CANF
Can-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares
CANF
Closed
$3.27
Closed
-(-)
At close
Get professional financial guidance
Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply
About
Can-Fite BioPharma Ltd. is a biopharmaceutical company, which engages in the development of drugs for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company is headquartered in Petah Tikva, Central(Hamerkaz) and currently employs 5 full-time employees. The company went IPO on 2005-09-22. The firm co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Its technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.
Key stats
Open
$3.27
Volume
42.95K
Market cap
$23.92M
Prev. close
$3.27
Impl / hst vl
-
Open interest
$0.00
$3.27
Day’s Range
$3.27
$0.19
52W Range
$5.98
Valuation
44
Valuation score
Fairly Valued
P/E
-
P/S
12.93
P/B
1.40
Current ratio
3.46
Debt / Equity
-0.99
ROE
-300.82%
Gross margin
-
Income growth
101.56%
FCF growth
-11.68
Analysts estimates
Consensus rating
Buy
The average rating from top 4 analysts indicates that stock is expected to perform in line with the market
Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$3.46
The top 3 analysts forecasts that 12-month price may increase by 5.74%, with a low of $3.42 and a high of $3.56
$3.42
Low
$3.46
Avg
$3.56
High
Current price
Earnings
Q4 ‘25 revenue
$405.00K
Q4 ‘25 net income
-$9.83M
Revenue
Net income
Previous EPS
-Estimate EPS
$0.00
Actual EPS
Estimate EPS
Explore the Healthcare sector
Get professional financial guidance
Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply